Role of suPAR in Periodontitis and CVD

Study Overview
=================
Brief Summary
-----------------
soluble urokinase-type plasminogen activator receptor (suPAR) plays a key role in endothelial function and may be a link for the known interaction of periodontitis and cardiovascular disease (CVD). The investigators compared the impact of gingival health, periodontitis (CP), CHD or of both diseases (CP+CHD) on saliva and serum suPAR levels.

Detailed Description
-----------------
The aim of this study was to evaluate a possible association between both saliva and serum suPAR levels in patients with CP and with CVD and if the serum suPAR levels are mediated by serum CRP.

Official Title
-----------------
Evaluation of Plasma and Salivary suPAR in Periodontitis and CVD Patients

Conditions
-----------------
Metabolic Disturbance, Periodontal Diseases

Intervention / Treatment
-----------------
* Other: Observation of suPAR plasma and salivary levels


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Presence of at least 15 teeth CP with a minimum of 40% of sites with a clinical attachment level (CAL) ≥2mm and probing depth (PD) ≥4mm; Presence of at least ≥2 mm of crestal alveolar bone loss verified on digital periapical radiographs Presence of ≥40% sites with bleeding on probing (BOP) Exclusion Criteria: Intake of contraceptives Intake of immunosuppressive or anti-inflammatory drugs throughout the last three months prior to the study Status of pregnancy or lactation Previous history of excessive drinking Allergy to local anaesthetic Intake of drugs that may potentially determine gingival hyperplasia such as Hydantoin, Nifedipine, Cyclosporin A or similar drugs.

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Control<br>Healthy patients | Other: Observation of suPAR plasma and salivary levels<br>* Evaluation of suPAR plasma level and correlation of plasma suPAR levels with periodontal and cardiovascular disease<br>|
| Periodontitis<br>Patients with periodontitis | Other: Observation of suPAR plasma and salivary levels<br>* Evaluation of suPAR plasma level and correlation of plasma suPAR levels with periodontal and cardiovascular disease<br>|
| Cardiovascular disease<br>Patients with cardiovascular disease | Other: Observation of suPAR plasma and salivary levels<br>* Evaluation of suPAR plasma level and correlation of plasma suPAR levels with periodontal and cardiovascular disease<br>|
| Periodontitis + cardiovascular disease<br>Patients with Periodontitis + cardiovascular disease | Other: Observation of suPAR plasma and salivary levels<br>* Evaluation of suPAR plasma level and correlation of plasma suPAR levels with periodontal and cardiovascular disease<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical attachment level | evaluation of changes in clinical attachment level | 1-year |